A Collaborative Drug Therapy Agreement

Pharmacists were also given the opportunity to complete five additional modules to complete their competency list on the WSPA CCP Training Certificate. These modules included the initiation of fluoride treatment and filling protocols for anaphylaxis, contraception, bronchospasm and insulin. The conclusion of these modules did not affect students` grades. These modules have been removed from the necessary course materials due to coverage of these content in other courses and the limitation in time of this week-long course. The number of students who chose to complete these optional modules was also tracked. These modules and related evaluations, like the modules initially required, were completed in Blackboard LMS. El Rio Community Health Center cares for more than 75,000 people in Pima County, Arizona. In 2011, 20% of adult patients in El Rio (8,954 out of 44,952) had diagnosed high blood pressure, but only 67% of patients diagnosed were under control. Pharmacists in El Rio were encouraged to establish CPAs with the centre`s medical providers. These agreements allow pharmacists to work directly with patients to help them manage their hypertension and other chronic diseases such as diabetes and hyperlipidemia.

Under the CPA, pharmacists have the power to modify medications for patients. After the implementation of CDTM, El Rio reported improved clinical results (for example. B lower cholesterol and blood pressure levels), increased use of recommended screenings and reduced ER visits. The el Rio case study highlights some important considerations for the implementation of the CDTM. These considerations include the introduction of mission-based values through training and guidance, the admission of pharmacy trainees, and the use of comprehensive strategies and networks to improve patient care and strengthen potential partnerships that could expand the use of CPAs. National Pharmacy Boards and Commissions regulate pharmacy practice at the state level, resulting in national fluctuations in the use of collaborative drug therapy (CDTA) contracts, also known as collaborative practice agreements (CPAs). While many countries have CDTAs or CPAs, there are big differences in how they can be used. Some states limit the conditions that pharmacists can treat, the drugs they can prescribe and the training they must have.8 In Washington, the Pharmacy Practice Act has allowed all pharmacists to prescribe CDTA drugs since 1979.9 There are no restrictions on the population or conditions of illness they are allowed to treat in the agreements. In recent years, pharmaceutical practices in many countries have been adapted to the evolving role of pharmacists as members of integrated health teams. In California, Montana, New Mexico and North Carolina, an advanced practice pharmacy is assigned to qualified pharmacists, They have the right to prescribe, monitor, manage and distribute drugs.10 While expanding patient access to care is a complex and difficult problem, pharmacists are in an integrated position to provide extensive care to patients who have not received treatment.11 In 2012 , the Food and Drug Administration (FDA) has considered creating a class of pharmacists opposite the store or class of pharmacies opposed to drugs.11 Patients who are not being treated offer more advanced treatment.

The creation of a class of drug pharmacists would take into account the need for treatment in three ways: improved access to the care of patients and minor diseases, reducing costs for patients and the health care system and reducing the burden on physicians so that they can focus on critically ill or medically complex patients.13-15 Opposition has highlighted concerns about the quality of care. 15 In response to these concerns, the FDA has decided not to comment on the creation of a class of drug pharmacists.